Processa Pharmaceuticals Announces Positive Preclinical Data for NGC-Iri
19. August 2024 08:00 ET
|
Processa Pharmaceuticals, Inc.
Delivers more cancer-killing SN-38 molecules to tumor than irinotecan and Onivyde® Studies support potential benefit as an improved treatment with fewer side effects HANOVER, Md., Aug. 19, 2024 ...
Processa Pharmaceuticals to Present Data at the American Association for Cancer Research Annual Meeting
25. März 2024 08:15 ET
|
Processa Pharmaceuticals, Inc.
HANOVER, MD, March 25, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next...
Processa Pharmaceuticals Provides Interim Analysis from Ongoing Phase 1b Trial of Next Generation Capecitabine Showing Improved Safety Over Capecitabine
19. Dezember 2023 09:00 ET
|
Processa Pharmaceuticals, Inc.
FDA acknowledges that NGC-Cap is a New Chemical Entity given the changes to metabolism and distribution of its major metabolite 5-FU Interim analysis of the NGC-Cap Phase 1b data shows improved...
Processa Pharmaceuticals to Present at the Sidoti & Co. Micro Cap Virtual Conference
10. August 2023 16:15 ET
|
Processa Pharmaceuticals, Inc.
HANOVER, MD, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company now focused on developing the next...
Processa Pharmaceuticals To Present an Update on Its Future Therapeutic Focus and Strategy at the Biotech Showcase on January 11, 2023.
04. Januar 2023 08:30 ET
|
Processa Pharmaceuticals, Inc.
HANOVER, MD, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), Dr. David Young, Processa Pharmaceuticals, CEO will present an update on Processa’s future therapeutic...
Processa Pharmaceuticals Announces Third Quarter Financial Results and Provides Corporate Update
08. November 2022 16:00 ET
|
Processa Pharmaceuticals, Inc.
PCS12852 successfully demonstrates a positive effect on the gastric emptying rate, clearing the path for a Phase 2B trial in 2023.Next Generation Capecitabine (a combination of PCS6422 and...
Processa Pharmaceuticals Appoints Khoso Baluch and James Neal to its Board of Directors and Justin Yorke to Chairman of the Board
16. August 2022 08:30 ET
|
Processa Pharmaceuticals, Inc.
Board Appointments Designed to Position Company for Anticipated Milestones While Ensuring Adherence to the Highest Governance Standards HANOVER, MD, Aug. 16, 2022 (GLOBE NEWSWIRE) -- Processa...
Processa Pharmaceuticals Doses First Patient in Amended Phase 1B Protocol for PCS6422 Combined with Capecitabine (Next Generation Capecitabine)
20. April 2022 08:30 ET
|
Processa Pharmaceuticals, Inc.
Processa focuses on identifying the PCS6422 regimens to increase capecitabine potency while identifying the MTD of Next Generation Capecitabine The amended protocol will provide a more precise...
Processa Pharmaceuticals Announces Year-End 2021 Results and Provides Corporate Update
30. März 2022 16:00 ET
|
Processa Pharmaceuticals, Inc.
Targeting Major Milestones 2022 HANOVER, Md., March 30, 2022 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) ("Processa" or the "Company"), a clinical stage company developing...
Processa Pharmaceuticals Announces Second Quarter 2021 Results and Provides Corporate Update
12. August 2021 17:15 ET
|
Processa Pharmaceuticals, Inc.
Adds fourth clinical asset, RX-3117, and targets major milestones in the second half of 2021 HANOVER, Md., Aug. 12, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a...